The increasing and often unaffordable cost of prescription drugs in this country is a near-constant topic of discussion within the healthcare industry. The Biden Administration has pursued several “aggressive legislative reforms” and other agency actions for addressing this issue, from authorizing Medicare to negotiate prescription drug prices directly with drug companies, to approving Florida’s request to import certain prescriptions from Canada at lower prices, to pushing pharmaceutical companies to cap the cost of insulin.
But states are also taking matters into their own hands – and this week Colorado made history by moving forward with placing a cap on the cost of an expensive popular prescription drug, making it the first state in the nation planning to limit what state-regulated health plans pay for medicine.
This decision was made by the Colorado Prescription Drug Affordability Board, or PDAB. These boards are typically comprised of state-appointed healthcare experts and stakeholders, and use criteria outlined in statutes to identify and evaluate certain drugs and conduct affordability reviews. Some boards, like Colorado’s, have the authority to set these so-called upper payment limits for the drugs they identify as creating an affordability challenge. PDABs are a relatively recent invention, first seen in Maryland in 2019, but have quickly grown in popularity; the National Academy for State Health Policy, which wrote and published the model legislation for these boards, reports that 16 states are considering legislation enacting PDABs in 2024 (so far).
Colorado is widely considered the most developed PDAB. It completed its initial selection of five drugs on which to conduct an affordability review back in August. This week it declared one of those drugs, an arthritis treatment called Enbrel, unaffordable for Colorado residents, and voted to move to the rulemaking process to establish a payment limit on the drug beginning next year. The Colorado All Payer Claims Database showed that Enbrel costs about $46,000 per patient per year, with patients responsible for about $2,300 of that. A supporter of the vote indicated that in addition to simply cutting costs for any drugs on which an upper limit is placed, the Board’s ability to set limits is a tremendous positive, because manufacturers would likely take the PDAB’s authority into account when setting prices in the first place. There has been no open discussion on what the Board plans to cap the drug’s price at, but there are those expressing concern, warning of potential legal action, and taking actions to limit the scope of the PDAB.
The pharmaceutical industry has repeatedly expressed opposition to upper payment limits, and the response to the vote in Colorado was no different. An industry trade group’s spokesperson expressed concern about the Board not considering other reasons that drug prices have increased, and the Arthritis Foundation has stated that a payment limit would not necessarily influence what the patient pays. Legal experts indicate that pharmaceutical companies could likely cite that upper payment limits violate the Fifth Amendment’s due process clause and takings clause, as well as the Constitution’s commerce clause, which gives Congress the authority to regulate transactions among states.
In response to the PDAB’s actions, Colorado lawmakers have proposed legislation that would preempt orphan drugs (drugs for rare diseases or conditions) from the PDAB’s purview: drugs like Embrel. Sponsors of the bill have stated that setting payment limits on these drugs could cool innovation and push manufacturers to stop selling the drug due to financial loss. The bill has thus far passed through its first committee and will be headed to the Colorado Senate floor this month.
With an election year, we can definitely expect to see more from states pushing through healthcare legislation where the federal government is perhaps falling short. For other states considering options such as capping drug prices, all eyes are on how Colorado’s PDAB fares these next few months.
The Medicare audit landscape has undergone a fundamental transformation, evolving from ad hoc enforcement practices to scientifically rigorous methodological frameworks. This evolution spans two critical
It’s two weeks into November, and still no Outpatient Prospective Payment System (OPPS) Final Rule from the Centers for Medicare & Medicaid Services (CMS). Now,
Please log in to your account to comment on this article.
Accurately determining the principal diagnosis is critical for compliant billing, appropriate reimbursement, and valid quality reporting — yet it remains one of the most subjective and error-prone areas in inpatient coding. In this expert-led session, Cheryl Ericson, RN, MS, CCDS, CDIP, demystifies the complexities of principal diagnosis assignment, bridging the gap between coding rules and clinical reality. Learn how to strengthen your organization’s coding accuracy, reduce denials, and ensure your documentation supports true medical necessity.
Denials continue to delay reimbursement, increase administrative burden, and threaten financial stability across healthcare organizations. This essential webcast tackles the root causes—rising payer scrutiny, fragmented workflows, inconsistent documentation, and underused analytics—and offers proven, data-driven strategies to prevent and overturn denials. Attendees will gain practical tools to strengthen documentation and coding accuracy, engage clinicians effectively, and leverage predictive analytics and AI to identify risks before they impact revenue. Through real-world case examples and actionable guidance, this session empowers coding, CDI, and revenue cycle professionals to shift from reactive appeals to proactive denial prevention and revenue protection.
Sepsis remains one of the most frequently denied and contested diagnoses, creating costly revenue loss and compliance risks. In this webcast, Angela Comfort, DBA, MBA, RHIA, CDIP, CCS, CCS-P, provides practical, real-world strategies to align documentation with coding guidelines, reconcile Sepsis-2 and Sepsis-3 definitions, and apply compliant queries. You’ll learn how to identify and address documentation gaps, strengthen provider engagement, and defend diagnoses against payer scrutiny—equipping you to protect reimbursement, improve SOI/ROM capture, and reduce audit vulnerability in this high-risk area.
Only ICD10monitor delivers what you need: updates on must-know changes associated with the FY26 IPPS, including new ICD-10-CM/PCS codes, CCs/MCCs, and MS-DRGs, plus insights, analysis and answers to your questions from two of the country’s most respected subject matter experts.
Get clear, practical answers to Medicare’s most confusing regulations. Join Dr. Ronald Hirsch as he breaks down real-world compliance challenges and shares guidance your team can apply right away.
Federal auditors are zeroing in on Inpatient Rehabilitation Facility (IRF) and hospital rehab unit services, with OIG and CERT audits leading to millions in penalties—often due to documentation and administrative errors, not quality of care. Join compliance expert Michael Calahan, PA, MBA, to learn the five clinical “pillars” of IRF-PPS admissions, key documentation requirements, and real-life case lessons to help protect your revenue.
During this essential RACmonitor webcast Michael Calahan, PA, MBA Certified Compliance Officer, will clarify the rules, dispel common misconceptions, and equip you with practical strategies to code, document, and bill high-risk split/shared, incident-to & critical care E/M services with confidence. Don’t let audit risks or revenue losses catch your organization off guard — learn exactly what federal auditors are looking for and how to ensure your documentation and reporting stand up to scrutiny.
Learn how to navigate the proposed elimination of the Inpatient-Only list. Gain strategies to assess admission status, avoid denials, protect compliance, and address impacts across Medicare and non-Medicare payors. Essential insights for hospitals.
Happy National Doctor’s Day! Learn how to get a complimentary webcast on ‘Decoding Social Admissions’ as a token of our heartfelt appreciation! Click here to learn more →
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24
